Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 12, 2020

Primary Completion Date

May 28, 2021

Study Completion Date

May 28, 2021

Conditions

Type 2 Diabetes

Interventions

DRUG

IBI362

Administrated by subcutaneous injection

DRUG

Placebo

Administrated by subcutaneous injection

DRUG

Dulaglutide

Administrated by subcutaneous injection

Trial Locations (1)

China Japan Friendship Hospital, Beijing

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04466904 - Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM | Biotech Hunter | Biotech Hunter